Elawyers Elawyers
Washington| Change

EVANS v. BRISTOL-MYERS SQUIBB COMPANY, 14-2657 EMC. (2014)

Court: District Court, N.D. California Number: infdco20140708b05 Visitors: 12
Filed: Jun. 24, 2014
Latest Update: Jun. 24, 2014
Summary: JOINT STIPULATION AND [PROPOSED] ORDER TO STAY LITIGATION PENDING TRANSFER TO THE PLAVIX MDL EDWARD M. CHEN, District Judge. This Joint Stipulation is made by and between Plaintiffs in Evans et al. v. Bristol-Myers Squibb Co. et al., No. CV-14-2655 JSW (N.D. Cal.), and Defendants Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Sanofi US Services Inc., and Sanofi-Synthelabo Inc., 1 (collectively "Defendants"), by and through the undersigned counsel of record, with reference to
More

JOINT STIPULATION AND [PROPOSED] ORDER TO STAY LITIGATION PENDING TRANSFER TO THE PLAVIX® MDL

EDWARD M. CHEN, District Judge.

This Joint Stipulation is made by and between Plaintiffs in Evans et al. v. Bristol-Myers Squibb Co. et al., No. CV-14-2655 JSW (N.D. Cal.), and Defendants Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Sanofi US Services Inc., and Sanofi-Synthelabo Inc.,1 (collectively "Defendants"), by and through the undersigned counsel of record, with reference to the following facts:

1. WHEREAS, on February 12, 2013, the Judicial Panel on Multidistrict Litigation ("JPML") established a multidistrict Plavix® litigation in the District of New Jersey, assigned to Judge Freda Wolfson;

2. WHEREAS, on June 6, 2014, Plaintiffs filed the Evans action in the Superior Court of California, San Francisco County;

3. WHEREAS, on June 9, 2014, the Evans action was removed to this Court by Defendants;

4. WHEREAS, on June 11, 2014, Defendants tagged this case for transfer to the Plavix® MDL and anticipates that the JPML will finalize a conditional transfer order for this case soon; and

5. WHEREAS, the Parties agree that the Evans action should be stayed pending its anticipated transfer to the Plavix® MDL in the District of New Jersey.

THEREFORE, IT IS HEREBY STIPULATED AND AGREED, subject to the Court's approval, that the Evans action should be stayed pending its anticipated transfer to the Plavix® MDL in the District of New Jersey.

IT IS SO STIPULATED.

PURSUANT TO STIPULATION, IT IS SO ORDERED.

FootNotes


1. Sanofi-Aventis U.S. LLC was incorrectly designated as "Sanofi-Aventis U.S. LLC.," Sanofi-27 Aventis U.S. Inc. was incorrectly designated as "Sanofi-Aventis U.S., Inc.," and Sanofi-Synthelabo Inc. was incorrectly designated as "Sanofi-Synthelabo, Inc." in the Complaint. As of June 11, 2012, 28 Sanofi-Aventis U.S. Inc. changed its name to Sanofi US Services Inc.
Source:  Leagle

Can't find what you're looking for?

Post a free question on our public forum.
Ask a Question
Search for lawyers by practice areas.
Find a Lawyer